Accelerate Diagnostics Long Term Debt

Accelerate Diagnostics (AXDX) currently reports a long-term debt of $47M as of December 2024. That compares with $36M in the prior-year period — up 29.7% year over year. Use the charts on this page to explore Accelerate Diagnostics's long-term debt history and peer comparisons.

Accelerate Diagnostics's long-term debt increased from $36M to $47M — a 29.7% year-over-year increase (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Accelerate Diagnostics reported $47M in long-term debt as of December 2024. That compares with $36M in the prior-year period — up 29.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $47M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Accelerate Diagnostics, and consider following AXDX for alerts when major investors trade the stock.

Accelerate Diagnostics is classified in the Healthcare sector. On long-term debt, it currently shows $47M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AXDX with unrelated industries.